Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate
Initiated in March 2019, this Research and Development partnership is focused on the identification of LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix® platform and their potential to act as therapeutic agents against Parkinson’s disease, drawing on Servier and Oncodesign’s complementary expertise in the field of neurodegenerative disease and kinase inhibitors.
[EN] InterSystems & Oncodesign partner for the optimization of data use to enhance and accelerate Drug Discovery processes in oncology
Home . Resources . [EN] InterSystems & Oncodesign partner for the optimization of data use to enhance and accelerate Drug Discovery processes in oncology
InterSystems and Oncodesign partner for the optimization of data use to enhance and accelerate Drug Discovery processes in oncology
As part of this new long-term partnership, Oncodesign will use the InterSystems IRIS for HealthTM solution to organize and leverage healthcare data to accelerate the search for new treatments in oncology using Artificial Intelligence (AI).
Paris, May 18th, 2021 – InterSystems, a leader in healthcare data management, and Oncodesign, a biopharmaceutical company specializing in precision medicine, today announced the signing of a strategic partnership aimed at advancing research for new treatments in the field of oncology.
In a context characterized by an exponential growth of data volumes over the last 20 years, the quality and use of health and research data have become two critical issues for all healthcare stakeholders. The current health crisis has only reinforced the importance of an agile and decompartmentalized strategy for health data governance.
As part of this partnership, Oncodesign has chosen to combine its proprietary platform for the identification and validation of new therapeutic targets, called OncoSNIPER, with InterSystems’ unified health data management platform, known as InterSystems IRIS for Health. This alliance will allow both companies to develop and optimize essential synergies between the two platforms.
The InterSystems IRIS for Health data platform will be integrated into Oncodesign’s recently established Artificial Intelligence (AI) Business Unit for the storage and management of various preclinical and clinical data sources, which are highly valuable to each of the businesses involved in the drug discovery process. By analyzing and better exploiting the data consolidated through InterSystems IRIS for Health, Oncodesign’s AI BU will optimize the development of OncoSNIPER, notably through more accurate functioning of its algorithms. In addition, InterSystems will provide Oncodesign with the benefit of its international network of strategic academic partners generating health data (hospitals and universities), particularly in North America.
For InterSystems, this partnership is part of a strategic approach to healthcare players through its access to Oncodesign’s solid expertise in drug discovery and reflects its historical commitment to oncology. With a solid domestic network, InterSystems has been working for many years with major cancer centers (known as CLCC in France) through its patient administrative and clinical management solution, InterSystems TrakCare (especially in Dijon, Nice and Reims), as well as with the Toulouse University Cancer Institute – Oncopole (IUCT-O) with InterSystems HealthShare, for comprehensive patient management and better coordination of the various private and public players in the region. The company has also made its expertise in health data exploitation available to innovative partners such as the start-up MyPL and the Guerbet Group.
For Michel Amous, Regional Director EMEA at InterSystems: “We are delighted to begin this partnership with Oncodesign, which has been a major player in the biotechnology industry for 25 years. Our goal is to provide them with our expertise in optimizing data platforms to build a new intelligent architecture for oncology research. The pooling of health data – scattered, heterogeneous but so valuable – is not just a simple operational consolidation. It is a project with strategic scope aimed at aggregating the various sources of data available to Oncodesign in order to improve communication between them. This dynamic governance will enable Oncodesign to remain at the forefront of biopharmaceutical innovation and ultimately to commercialize new therapeutic solutions to better serve the public interest. ”
For Oncodesign, this partnership is the second step in its strategic development based around AI after the launch in 2017 of the OncoSNIPER project (clinical trial of 600 patients with 3 oncology indications and 16 partners). After generating large amounts of heterogeneous clinical data, the company needs to structure the available data using the InterSystems IRIS for Health data platform, before implementing the algorithms needed to select sub-populations of patients with treatment-resistant cancers.
Philippe Genne, Chairman and CEO of Oncodesign, stated: “We have known the InterSystems teams well for several years, and we are therefore very pleased to formalize our collaboration through this ambitious partnership. Our expertise at Oncodesign is in developing new treatments and InterSystems’ is in leveraging data to accelerate the digital transformation of companies. Together, we will be able to pool our respective fields of expertise in order to make our drug discovery process in precision medicine more reliable and even faster. Traditionally, the lead optimization phase alone can last up to 3 years and cost between 10 and 12 million euros with random results in the medium term (1/10 success rate). Today, artificial intelligence is changing the game: the exploitation of data gives us the possibility to make more informed choices in increasingly rapid timeframes. ”
This collaboration will bring together several distinct and complementary fields of expertise, including data science, artificial intelligence, pharmacology, chemistry, biology and clinical research. The two companies share a common goal: to harness the power of data to develop and industrialize new therapeutic solutions in the field of oncology.
On May 21st next, Oncodesign will inaugurate its new headquarters in Dijon (Bâtiment Jean Mermoz – 18 rue Jean Mazen), which will house its AI teams. On the same day, the company will also launch its new development strategy based on AI approaches.
Established in 1978, InterSystems is the leading provider of data technology for extremely critical data in the healthcare, finance, and logistics sectors. Its cloud-first data platforms solve interoperability, speed, and scalability problems for large organizations around the globe. InterSystems also develops and supports unique managed services for hospital EMRs, unified care records for communities and nations, and laboratory information management systems. InterSystems is committed to excellence through its award-winning, 24×7 support for customers and partners in more than 80 countries. Privately held and headquartered in Cambridge, Massachusetts, InterSystems has 25 offices worldwide. For more information, please visit InterSystems.com.
Founded 25 years ago by Dr. Philippe Genne, the Company’s CEO and Chairman, Oncodesign is a biopharmaceutical company dedicated to precision medicine. With its unique experience acquired by working with more than 800 clients, including the world’s largest pharmaceutical companies, along with its comprehensive technological platform combining state-of-the-art medicinal chemistry, pharmacology, regulated bioanalysis, medical imaging and Artificial Intelligence, Oncodesign is able to predict and identify, at a very early stage, each molecule’s therapeutic usefulness and potential to become an effective drug. Applied to kinase inhibitors, which represent a market estimated at over $65 billion by 2027 and accounting for almost 25% of the pharmaceutical industry’s R&D expenditure, Oncodesign’s technology has already enabled the targeting of several promising molecules with substantial therapeutic potential, in oncology and elsewhere, along with partnerships with pharmaceutical groups such as Servier. Oncodesign is based in Dijon, France, in the heart of the town’s university and hospital hub, and within the Paris-Saclay cluster. Oncodesign has 233 employees and subsidiaries in Canada and the USA.
InterSystems Michel Amous Regional Managing Director EMEA Tel. : +33 (0)1 77 49 16 00 CommunicationFrance@intersystems.com
Edelman Media Relations Dominic Riding Tel : +33 (0)7 77 96 24 42 IntersystemsFrance@edelman.com
18 rue Jean Mazen - FR - 21000 Dijon Tel.+33 380 788 260